751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results

Autor:	Y. Lurie, Paul J. Pockros, Nezam H. Afdhal, B. Murphy, K. Lamon, Stuart C Gordon, M. Shiffinan, Yoon Jun Kim, M. Rodrieuez-Torres, Yves Benhamou
Rok vydání:	2006
Předmět:	Therapy naive chemistry.chemical_compound Hepatology chemistry business.industry Ribavirin Pegylated interferon alpha-2b Medicine Pharmacology business
Zdroj:	Journal of Hepatology. 44:S273
ISSN:	0168-8278
DOI:	10.1016/s0168-8278(06)80739-7
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::36d4681aa87323ee260e1e40d820b189 https://doi.org/10.1016/s0168-8278(06)80739-7 Zobrazit plný text záznamu Full Text from ScienceDirect